275 related articles for article (PubMed ID: 18018584)
1. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
2. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
3. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):301-4. PubMed ID: 17710895
[TBL] [Abstract][Full Text] [Related]
4. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
5. Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Yonsei Med J; 2007 Jun; 48(3):421-4. PubMed ID: 17594149
[TBL] [Abstract][Full Text] [Related]
6. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report].
Oida T; Shichiri Y; Takao N; Kanno T; Kanamaru H
Hinyokika Kiyo; 2005 Jul; 51(7):487-9. PubMed ID: 16119817
[TBL] [Abstract][Full Text] [Related]
7. Granulomas induced by subcutaneous injection of a luteinizing hormone-releasing hormone analog: a case report and review of the literature.
Watanabe T; Yamada N; Yoshida Y; Yamamoto O
J Cutan Pathol; 2010 Oct; 37(10):1116-8. PubMed ID: 19863702
[No Abstract] [Full Text] [Related]
8. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
9. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
10. [Cutaneous epithelioid granulomas caused by subcutaneous infusion of leuprorelin acetate: a case report].
Tachibana M; Yamano Z; Kusuda Y; Hara S; Shimogaki H; Hamami G
Hinyokika Kiyo; 2004 Mar; 50(3):199-202. PubMed ID: 15148774
[TBL] [Abstract][Full Text] [Related]
11. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
[TBL] [Abstract][Full Text] [Related]
12. Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings.
Ouchi T; Koyama T; Miyata N; Sugiura M
J Dermatol; 2006 Oct; 33(10):719-21. PubMed ID: 17040504
[TBL] [Abstract][Full Text] [Related]
13. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
14. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.
Watanabe T; Yamada N; Yoshida Y; Yamamoto O
J Cutan Pathol; 2009 Dec; 36(12):1299-302. PubMed ID: 19469875
[TBL] [Abstract][Full Text] [Related]
15. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth.
Dangle P; Palit V; Sundaram SK; Weston P
Urology; 2007 Apr; 69(4):779.e5-6. PubMed ID: 17445679
[TBL] [Abstract][Full Text] [Related]
16. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
17. [Adverse reaction of LH-RH agonist and its countermeasure].
Oishi K
Nihon Rinsho; 2000 Jul; 58 Suppl():202-5. PubMed ID: 11022714
[No Abstract] [Full Text] [Related]
18. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
19. [Long-acting depot of LH-RH agonist].
Akaza H
Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
[No Abstract] [Full Text] [Related]
20. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
